Pharmaceutical Preparations · DE · CIK 1799788
Greenwich LifeSciences develops GLSI-100, an immunotherapy to prevent breast cancer recurrences by targeting HER2/neu positive patients
Comparable business profile · signals at a glance
In the 90 days to Jan 13, 2026: 1 insider bought $489K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 13, 2026 | Patel SnehalCEO and CFO | Buy | 1,800 | $29.83 | $54K |
| Jan 12, 2026 | Patel SnehalCEO and CFO | Buy | 2,900 | $27.54 | $80K |
| Dec 31, 2025 | Patel SnehalCEO and CFO | Buy | 4,300 | $21.36 | $92K |
| Dec 30, 2025 | Patel SnehalCEO and CFO | Buy | 2,900 | $21.73 | $63K |
| Dec 18, 2025 | Patel SnehalCEO and CFO | Buy | 4,100 | $12.62 | $52K |
| Nov 25, 2025 | Patel SnehalCEO and CFO | Buy | 4,600 | $8.37 | $39K |
| Nov 7, 2025 | Patel SnehalCEO and CFO | Buy | 10,600 | $8.43 | $89K |
| Oct 31, 2025 | Patel SnehalCEO and CFO | Buy | 2,300 | $9.26 | $21K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.